Data demonstrates compelling clinical activity, highlights adagrasib potential as monotherapy in solid tumors Clinical data also presented at the ASCO Plenary Series: April 2023 Session Data follows recent inclusion of KRAZATI® (adagrasib) in NCCN Guidelines for CNS Cancers SAN DIEGO,…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.